Finally, the immunotherapeutic effect of HOXC13 in breast cancer was explored, and results showed that the group with higher expressed HOXC13 held higher anti-PD1/PDL1 response rates in four independent cohorts (Figure 9J). This evidence concerns the gene CD274 and breast carcinoma.